TY - JOUR T1 - Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension JF - Thorax JO - Thorax SP - 581 LP - 583 DO - 10.1136/thoraxjnl-2016-209701 VL - 73 IS - 6 AU - Luca Richeldi AU - Michael Kreuter AU - Moisés Selman AU - Bruno Crestani AU - Anne-Marie Kirsten AU - Wim A Wuyts AU - Zuojun Xu AU - Katell Bernois AU - Susanne Stowasser AU - Manuel Quaresma AU - Ulrich Costabel Y1 - 2018/06/01 UR - http://thorax.bmj.com/content/73/6/581.abstract N2 - The TOMORROW trial of nintedanib comprised a randomised, placebo-controlled, 52-week period followed by a further blinded treatment period and an open-label extension. We assessed outcomes across these periods in patients randomised to nintedanib 150 mg twice daily or placebo at the start of TOMORROW. The annual rate of decline in FVC was −125.4 mL/year (95% CI −168.1 to −82.7) in the nintedanib group and −189.7 mL/year (95% CI −229.8 to −149.6) in the comparator group. The adverse event profile of nintedanib remained consistent throughout the studies. These results support a benefit of nintedanib on slowing progression of idiopathic pulmonary fibrosis beyond 52 weeks. ER -